Literature DB >> 2612053

Role of IgG and complement component C5 in the initial course of experimental cryptococcosis.

F Dromer1, C Perronne, J Barge, J L Vilde, P Yeni.   

Abstract

Although cellular immunity has a crucial role during cryptococcosis, several in vitro studies have pointed out the importance of IgG anti-Cryptococcus neoformans antibodies and complement components during phagocytosis of the yeast by polymorphonuclear leucocytes and monocytes. We investigated the role of complement and specific antibodies in host defences against experimental cryptococcosis, using a monoclonal IgG1 antibody (E1) specific for cryptococcal capsular polysaccharide, and mice congenitally sufficient or deficient in the fifth component of complement (C5). During in vitro experiments, E1 and the normal mouse serum from C5-sufficient and -deficient mice were unable to inhibit the growth of C.neoformans. However, E1 was an efficient opsonin for the ingestion of C. neoformans by mouse peritoneal macrophages, acting in synergy with normal mouse serum. In vivo, E1 was protective in heavily infected C5-deficient mice (DBA/2) dying from an early acute pneumonia, but not in C5-sufficient mice (BALB/c) and in DBA/2 mice infected with a smaller inoculum dying from a late progressive meningo-encephalitis. Although protection against pneumonia is attributed to a local recruitment of phagocytes in C5-sufficient mice, this was not observed in C5-deficient mice protected with E1. In this case, IgG anti-C. neoformans antibodies seem to be an alternative for an efficient opsonization of the yeasts. Altogether, these data suggest that two main mechanisms may protect infected mice from an early fatal pneumonia: the efficient opsonization of the yeast by complement and the recruitment of phagocytes in infected tissues.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2612053      PMCID: PMC1534827     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Complement depletion in cryptococcal sepsis.

Authors:  A M Macher; J E Bennett; J E Gadek; M M Frank
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

2.  Antibody-dependent killing of Cryptococcus neopormans by human peripheral blood mononuclear cells.

Authors:  R D Diamond
Journal:  Nature       Date:  1974-01-18       Impact factor: 49.962

3.  Prognostic factors in cryptococcal meningitis. A study in 111 cases.

Authors:  R D Diamond; J E Bennett
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

4.  A major role of the fifth component of complement (C5) in the opsonization of yeast particles. Partial dichotomy of function and immunochemical measurement.

Authors:  M E Miller; U R Nilsson
Journal:  Clin Immunol Immunopathol       Date:  1974-01

5.  Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection.

Authors:  L K Cauley; J W Murphy
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

6.  Opsonization of Cryptococcus neoformans by human immunoglobulin G: role of immunoglobulin G in phagocytosis by macrophages.

Authors:  T R Kozel; T G McGaw
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

7.  Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.

Authors:  K A Laxalt; T R Kozel
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

8.  Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.

Authors:  T R Kozel; J L Follette
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

9.  Genetic control of susceptibility to Cryptococcus neoformans in mice.

Authors:  J C Rhodes; L S Wicker; W J Urba
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

10.  Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans.

Authors:  F M Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

View more
  34 in total

1.  Legionella pneumophila entry gene rtxA is involved in virulence.

Authors:  S L Cirillo; L E Bermudez; S H El-Etr; G E Duhamel; J D Cirillo
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

Review 2.  Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle.

Authors:  Arturo Casadevall
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

3.  Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes.

Authors:  F Dromer; J Barbet; J Bolard; J Charreire; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

4.  Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.

Authors:  J E Sanford; D M Lupan; A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

Review 5.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

6.  In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.

Authors:  Kileen L Mershon-Shier; Alex Vasuthasawat; Kazue Takahashi; Sherie L Morrison; David O Beenhouwer
Journal:  Mol Immunol       Date:  2011-07-01       Impact factor: 4.407

7.  Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.

Authors:  Marcio L Rodrigues; Li Shi; Eliana Barreto-Bergter; Leonardo Nimrichter; Sandra E Farias; Elaine G Rodrigues; Luiz R Travassos; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.

Authors:  A Vecchiarelli; C Retini; A Casadevall; C Monari; D Pietrella; T R Kozel
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Authors:  J Mukherjee; L S Zuckier; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.